JPWO2019217165A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217165A5 JPWO2019217165A5 JP2020544255A JP2020544255A JPWO2019217165A5 JP WO2019217165 A5 JPWO2019217165 A5 JP WO2019217165A5 JP 2020544255 A JP2020544255 A JP 2020544255A JP 2020544255 A JP2020544255 A JP 2020544255A JP WO2019217165 A5 JPWO2019217165 A5 JP WO2019217165A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- glp1r agonist
- phenyl
- agonist
- glp1r
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 1
- 108091005979 glycated hemoglobin Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668384P | 2018-05-08 | 2018-05-08 | |
| US62/668,384 | 2018-05-08 | ||
| PCT/US2019/030110 WO2019217165A1 (en) | 2018-05-08 | 2019-05-01 | Therapeutic uses of glp1r agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523877A JP2021523877A (ja) | 2021-09-09 |
| JPWO2019217165A5 true JPWO2019217165A5 (ru) | 2022-05-17 |
Family
ID=66484210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544255A Pending JP2021523877A (ja) | 2018-05-08 | 2019-05-01 | Ｇｌｐ１ｒアゴニストの治療的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210023072A1 (ru) |
| EP (1) | EP3790549A1 (ru) |
| JP (1) | JP2021523877A (ru) |
| KR (1) | KR20210005843A (ru) |
| AU (1) | AU2019266114A1 (ru) |
| CA (1) | CA3090823A1 (ru) |
| MX (1) | MX2020008387A (ru) |
| SG (1) | SG11202007966UA (ru) |
| TW (1) | TW202015683A (ru) |
| WO (1) | WO2019217165A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3157525A1 (en) | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20230174547A1 (en) * | 2020-04-01 | 2023-06-08 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor |
| CN115461344B (zh) * | 2020-04-01 | 2024-01-12 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂的晶型a及其制备方法 |
| WO2021238962A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | 一种制备glp-1受体激动剂的方法 |
| WO2022061091A1 (en) * | 2020-09-21 | 2022-03-24 | Vtv Therapeutics Llc | Amorphous form of isoquinoline derivative |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| PE20240362A1 (es) | 2021-04-21 | 2024-03-04 | Gilead Sciences Inc | Compuestos moduladores del glp-ir carboxibenzimidazolicos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1147094A1 (en) * | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| US7727983B2 (en) | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| DK2413693T3 (en) * | 2009-03-30 | 2015-11-16 | Vtv Therapeutics Llc | Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof |
| WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| JP2015510947A (ja) * | 2012-03-22 | 2015-04-13 | トランステック・ファーマ，エルエルシー | 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用 |
| AU2014207748B2 (en) * | 2013-01-17 | 2018-10-11 | Vtv Therapeutics Llc | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
-
2019
- 2019-05-01 JP JP2020544255A patent/JP2021523877A/ja active Pending
- 2019-05-01 EP EP19723616.9A patent/EP3790549A1/en active Pending
- 2019-05-01 CA CA3090823A patent/CA3090823A1/en active Pending
- 2019-05-01 AU AU2019266114A patent/AU2019266114A1/en active Pending
- 2019-05-01 SG SG11202007966UA patent/SG11202007966UA/en unknown
- 2019-05-01 MX MX2020008387A patent/MX2020008387A/es unknown
- 2019-05-01 WO PCT/US2019/030110 patent/WO2019217165A1/en unknown
- 2019-05-01 KR KR1020207026027A patent/KR20210005843A/ko unknown
- 2019-05-07 TW TW108115702A patent/TW202015683A/zh unknown
-
2020
- 2020-10-13 US US17/069,453 patent/US20210023072A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6676108B2 (ja) | ２型糖尿病の処置のためのリキシセナチド及びメトホルミン | |
| Hollander et al. | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors | |
| US8017633B2 (en) | Roflumilast for the treatment of diabetes mellitus | |
| JP6066144B2 (ja) | 併用医薬 | |
| EP2771024B1 (en) | Treatment protocol of diabetes type 2 | |
| KR101983982B1 (ko) | 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물 | |
| US20110118180A1 (en) | Method of treatment of diabetes type 2 comprising add-on therapy to metformin | |
| KR20140041409A (ko) | ２형 진성 당뇨병 환자에서 저혈당증의 예방 | |
| US20210023072A1 (en) | Therapeutic uses of glp1r agonists | |
| KR20140038410A (ko) | 2형 당뇨병에서 기저 인슐린에 대한 부가 치료요법으로서의 릭시세나티드 | |
| EA034940B1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| JPWO2019217165A5 (ru) | ||
| TWI519297B (zh) | 使用雙醋瑞因之糖尿病輔助療法 | |
| CN111246859B (zh) | 含有锌盐、环二肽-组氨酸脯氨酸及作为有效成分的抗糖尿药物的糖尿病预防或治疗用药学组合物 | |
| JP6438389B2 (ja) | 減量法 | |
| WO2006094942A1 (en) | Roflumilast for the treatment of diabetes mellitus | |
| Makkar et al. | Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes Mellitus | |
| Barnett | Potential role of oral DPP‐4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents | |
| CN116850188A (zh) | 川芎嗪硝酮衍生物在制备预防或治疗2型糖尿病药物中的应用 | |
| JP2011105609A (ja) | メトホルミンへの付加療法を含む２型糖尿病の治療方法 |